Mismatch repair–deficient (dMMR) rectal cancers are highly immunogenic due to their elevated neoantigen burden, making them particularly sensitive to immune checkpoint blockade. Prior studies with PD-1 inhibitors alone have already shown remarkable clinical complete response rates, raising the possibility of non-operative management strategies. The RESET-R trial builds on this concept by exploring whether an even shorter course of dual checkpoint inhibition could achieve rapid and durable tumor eradication.
Colorectal Cancer: Epidemiology, Pathogenesis, Diagnosis, and Therapeutic Advances
Study Design and Methods
RESET-R is a multicenter, single-arm Phase 2 trial evaluating a short-course neoadjuvant regimen combining Nivolumab and Ipilimumab in patients with stage I–III dMMR rectal cancer.
Patients received:
- One cycle of nivolumab + ipilimumab
- A second cycle only if early response was incomplete
The primary endpoint was clinical complete response (cCR) at day 93, assessed using digital rectal examination, endoscopy, MRI, and biopsy when necessary. Patients achieving cCR were managed with a watch-and-wait approach, avoiding immediate surgery.
Results
The interim analysis demonstrates an exceptionally high level of efficacy with this minimal treatment approach:
- Clinical complete response: 100% (16/16 patients)
- After one cycle: ~69% achieved cCR
- After two cycles: ~31% achieved cCR
- Disease control: no progression or recurrence at median 16 months follow-up
- Safety: grade 3 immune-related adverse events in ~19%, no grade 4–5 toxicity
Interpretation
These findings indicate that even one or two cycles of dual checkpoint blockade can induce rapid and complete tumor regression in dMMR rectal cancer. The absence of early relapse supports the biological depth of response, while the manageable toxicity profile reinforces the feasibility of this approach.
Why This Matters
RESET-R represents a major step toward treatment de-escalation in oncology. Instead of combining multiple modalities (chemotherapy, radiotherapy, surgery), this strategy suggests that immunotherapy alone may be sufficient in highly selected patients.
If confirmed in larger cohorts with longer follow-up, this approach could:
- Redefine standard care toward organ preservation
- Eliminate the need for chemoradiotherapy in selected patients
- Establish short-course immunotherapy as a curative-intent strategy
Ultimately, this trial strengthens the growing concept that tumor biology—not treatment intensity—should guide therapeutic decisions in modern oncology.
Read Full Article Here.